Skip Navigation



Rheumatology Advance Access published online on February 19, 2007
Rheumatology, doi:10.1093/rheumatology/kel429
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
46/5/730    most recent
kel429v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Brune, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brune, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Editorial

Do case control studies on coxibs tell us anything new?

K. Brune

Correspondence to: Dr Brune. E-mail: Kay.Brune@pharmakologie.med.uni-erlangen.de

The first 10% of the full text of this article appears below.

If one reads the voluminous manuscript by Rahme and Nedjar (this issue) one gets—at the first glance—the impression that this is all known:

  1. Paracetamol and celecoxib exert the least damaging effect on the GI-tract and the cardiovascular system.
  2. Neither compound goes along with an increased cardiovascular risk in patients not receiving low dose aspirin.
  3. Low dose aspirin increases the GI-toxicity . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?